128 results about "Autoantibody" patented technology

A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine / adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

The application belongs to the technical field of biomedical detection, and particularly relates to a biomarker for lung cancer diagnosis and application thereof. A new lung cancer biomarker anti-FDX1 autoantibody is found for the first time, and the expression level of the plasma anti-FDX1 autoantibody can be detected to distinguish lung cancer patients from normal people, and the experimental results also show that the anti-FDX1 autoantibody can be used as a detection index for different clinical characteristics of lung cancer. Further, the anti-FDX1 autoantibody is combined with carcinoembryonic antigen to construct a new lung cancer detection model as a marker, and experimental data show that the combined model can significantly improve the lung cancer detection efficiency, which has important significance for lung cancer diagnosis.

The present invention is directed to multispecific molecules that bind immunoglobulin and a recycling target. Binding immunoglobulin and a recycling target results in degradation of immunoglobulin and in certain embodiments recycling of the multispecific molecule. The multispecific molecules of the present invention are thought to be useful in the treatment of autoantibody-induced diseases.

The present disclosure relates to human antibodies specific to dermatomyositis antigen peptides, preparation methods and uses. Specifically, the present disclosure relates to a monoclonal antibody that specifically binds to MDA5 antigen protein, a preparation method of the monoclonal antibody and a use of the aforementioned monoclonal antibody in the preparation of a drug for the diagnosis, prevention or treatment of inflammatory myopathy or its complications. The antibody or antigen-binding fragment against MDA5 screened by the present disclosure specifically binds to MDA5 antigen, can be used as a reference standard for qualitative detection of MDA5 positivity, realizes qualitative or quantitative detection of the level of anti-MDA5 autoantibody in patients with inflammatory myopathy or its complications, and has important significance for the clinical diagnosis, disease monitoring and treatment of patients with DM, CAMD, DM-ILD, CADM-ILD and the like.

The application provides an autoantibody marker for predicting the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, a series of autoantibody marker molecules are screened by detecting autoantibodies against different antigen targets in blood of lung cancer patients in the third stage, and the autoantibody marker molecules have great correlation with the prediction of the effect of lung cancer immunneoadjuvant therapy, and three autoantibody biomarkers with better prediction of the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage are further screened by combining with a CART decision tree strategy; the combination of the autoantibody biomarkers can be used for efficiently predicting whether the lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage is effective, providing a reference basis for a clinician to decide a treatment scheme, providing a new prediction means for the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, and having important scientific significance and clinical application value.

The application provides a method for constructing an animal model of systemic lupus erythematosus, and the animal model of systemic lupus erythematosus shows high autoantibody, low complement, high inflammatory factor and severe kidney damage. The animal model of systemic lupus erythematosus provided by the application has a clear cause, can cause abnormalities of innate immunity and acquired immunity systems, and has a short experimental cycle, thereby providing a new animal model for drug candidate screening, drug treatment effect evaluation and pathogenesis research of systemic lupus erythematosus.

The invention relates to a chimeric autoantibody receptor (CAAR) comprising an autoantigen of a Contactin-associated protein-like 2 (CASPR2) protein or one or more autoantigenic fragments thereof. The invention relates further to a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid comprising a sequence encoding an autoantigen, wherein said autoantigen comprises or consists of Contactin-associated protein-like 2 (CASPR2) or one or more fragments thereof, a sequence encoding a transmembrane domain, and a sequence encoding an intracellular signaling domain. The invention further relates to a nucleic acid vector comprising a nucleic acid molecule encoding the chimeric autoantibody receptor (CAAR) of the invention. The invention relates further to a genetically modified cell comprising a nucleic acid molecule or a vector of the invention and / or expressing a CAAR according to the invention.

The present disclosure relates to the field of clinical detection technology, in particular, to the application of triiodothyronine autoantibody as a marker of thyroid dysfunction during cancer treatment. The present disclosure can help clinicians to judge the real thyroid function status of patients and improve the accuracy of diagnosis.

The present disclosure provides inter alia, molecules comprising an autoantibody-binding domain and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic autoantibodies.

The application belongs to but is not limited to the field of biomedical technology, and discloses application of anti-ACSL6 autoantibody as a prognostic evaluation marker for lung adenocarcinoma. Compared with traditional markers, the circulating biomarker anti-ACSL6 autoantibody has the characteristics of specificity, stability, early production, non-invasiveness, easy detection and the like, and has more potential value in reflecting the prediction of patient prognosis. High expression of anti-ACSL6 autoantibody is often related to poor survival of LUAD patients, and patients with low expression show relatively better prognosis. And anti-ACSL6 autoantibody remains significant in multivariate Cox regression, indicating that it can independently predict the survival outcome of patients after adjusting various confounding factors such as gender, age, stage, metastasis status and the like. This enables anti-ACSL6 autoantibody to provide more accurate risk stratification basis for clinicians, and help to develop individualized treatment and follow-up plans.

This invention provides a serum protein biomarker for early screening and diagnosis of pancreatic ductal adenocarcinoma. The serum protein biomarker is one or a combination of two or more autoantibodies against tumor-associated antigens HEXB, TXLNA, and SLAMF6. The invention also provides the application of reagents, kits, and analytical methods for detecting the serum protein biomarker. This invention screens for autoantibodies against pancreatic ductal adenocarcinoma-associated antigens. By measuring the expression levels of these indicators in the serum of patients with pancreatic ductal adenocarcinoma, healthy controls, and controls with benign pancreatic diseases, the screened anti-HEXB, anti-TXLNA, and anti-SLAMF6 autoantibodies can distinguish between pancreatic ductal adenocarcinoma, healthy controls, and benign pancreatic diseases. Furthermore, this invention designs and optimizes combinations of tumor-associated antigens for the diagnosis of pancreatic ductal adenocarcinoma. Applying the optimized antigens to an ELISA kit and detecting serum anti-TAA autoantibodies using an indirect enzyme-linked immunosorbent assay (ELISA) can accurately identify patients with pancreatic ductal adenocarcinoma, healthy controls, and patients with benign pancreatic diseases.

Materials and methods are provided herein for detecting the presence of an autoantibody specific for PDE10A to identify the mammal as having an autoimmune neurological disorder as well as methods and materials for treating an autoimmune neurological disorder. Materials and methods also are provided herein for treating cancer and / or neurological autoimmunity in a mammal using an immune checkpoint inhibitor and detecting the presence of an autoantibody specific for PDE10A to monitor for the development of neurologic complications in the mammal.

The utility model discloses a kit for detecting M-type phospholipase A2 receptor autoantibody, which relates to the technical field of biological detection and comprises a kit body, a drawing box is slidably connected in the kit body, an empty slot is arranged at the top end of the kit body, a placing box is slidably connected in the empty slot, the top end of the placing box is rotatably connected to a kit cover, and the drawing box is arranged in the box cover. A placing groove is formed in the placing box, the limiting mechanism comprises a storage groove formed in the drawing box, fixing assemblies used for assisting in taking are fixedly connected to the two sides of the inner wall of the box body, and a clamping block is fixedly connected to one end of a spring rod; the taking mechanism is arranged in the box body, and the taking mechanism is used for assisting a worker to quickly take the stored detection antibody. The kit disclosed by the utility model has the effects that a user can conveniently take the test paper, and meanwhile, the test paper can be stored in a daily limiting manner.

Provided herein are compounds, including compounds of any of the formulae described herein (e.g., Formula (I'), Formula (I), Formula (II)), and pharmaceutically acceptable salts thereof. Compounds provided herein are capable of covalently binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins and are therefore useful in the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

The application discloses polypeptide markers based on autoantibodies and application thereof in early lung cancer diagnosis, and relates to the technical field of biological detection. The application finds that there are 143 polypeptide probes with significant signal differences between a lung adenocarcinoma group in early stage and a healthy population group through research and analysis of plasma samples of the two groups, and further screens 14 polypeptide probes that can produce more stable signal differences between the two groups. Through attempts of various machine learning methods, it is found that a classification model can be established by taking the signal value accumulation of the 14 polypeptide probes as an index for model construction, thereby providing a path for effective diagnosis of early lung adenocarcinoma.

The invention provides a chimeric antigen receptor targeting CD19 and / or CD20 and application thereof, the chimeric antigen receptor comprises: an extracellular domain capable of binding to CD20 and / or CD19; the extracellular domain is connected with the amino acid sequence, the transmembrane domain is connected with the extracellular domain, the intracellular domain is connected with the transmembrane domain, and the intracellular domain is selected from all amino acid sequences or partial amino acid sequences of at least one of the following proteins: 2B4, DAP10 and CD3zeta. The chimeric antigen receptor disclosed by the invention has double-target recognition capability and can be simultaneously combined with CD19 and CD20, so that the chimeric antigen receptor can cover a full differentiation stage of pathogenic B cells in autoimmune diseases and block a production path of an autoantibody from a source of a pathological mechanism; meanwhile, based on the inherent regulation and control capability of NK cells on lesion T cells, pathogenic T cells are removed, and the removal effect of B cells is cooperated, so that bidirectional blocking treatment on autoimmune pathology is realized.

The present invention includes a method of characterizing disease activity in a systemic lupus erythematosus patient (SEE), comprising: obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, wherein the dataset comprises data representing the level of one or more biomarkers in the blood, serum, plasma or urine sample from each of (b) to (g); at least one innate serum or plasma mediator biomarker; at least one adaptive serum or plasma mediator; at least one chemokine / adhesion molecule biomarker; at least one soluble TNF superfamily biomarker; the inflammatory mediator biomarker SCF; at least one SLE-associated autoantibody specificity biomarker; and calculating a Lupus Disease Activity Immune.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR.

The invention relates to a method for improving the benefit of a therapy or therapeutic agent to a subject. The method comprises administering to the subject an agent which reduce Fc receptor binding of serum IgG molecules in the subject; and subsequently administering said therapy or therapeutic agent to the subject. The invention also related to a method for administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject and optionally (b) subsequently subjecting the subject to a treatment which removes endogenous autoantibodies. The invention also relates to a kit for carrying out a method of the invention.

A method for preparing therapeutic blood products from pooled plasma donors is provided. The therapeutic blood products include, for example, plasma, plasma proteins, and plasma fractions, in which safety is improved by reducing or eliminating the concentration of donor autoantibodies against FcεRIβ.

The invention relates to a D62A site modified anti-IFN-gamma autoantibody escape mutant and application thereof, and relates to the technical field of biological medicine and immunotherapy. The D62A site modified anti-IFN-gamma autoantibody escape mutant is an IFN-gamma mutant, and compared with a wild type IFN-gamma, the D62A site modified anti-IFN-gamma autoantibody escape mutant not only can escape combination of an anti-IFN-gamma autoantibody, but also retains the activity of combination with an IFN-gamma receptor 1 (IFNGR1), so that the mutant can effectively fill a part of treatment blind areas of a patient group insensitive to other mutation sites, and the treatment effect of the patient group is improved. And the method can also be used for identifying patients sensitive to the mutant in an AIGA patient group, so that a foundation is laid for guiding clinical precise medication.

Provided herein is a method and kit that accurately measure autoantibody activity against a TSH receptor without pretreating a blood sample. The autoantibody activity against a TSH receptor in a blood sample is measured by using a kit for measurement of autoantibody activity against a TSH receptor in a mammal cell, comprising a mammal cell expressing both a cAMP biosensor and the TSH receptor, and a substrate capable of visualizing and / or quantifying the cAMP biosensor as constituents, and performing the steps of: (a) incubating a mammal cell expressing both a cAMP biosensor and the TSH receptor in the presence of a blood sample collected from a test subject; (b) measuring an activation level of the cAMP biosensor after the step (a); and (c) comparing the activation level measured in the step (b) with an activation level in a control to calculate the autoantibody activity.

The invention relates to the technical field of medicines, and particularly discloses a medicine and a method for treating diseases caused by autoantibodies generated by excessive proliferation of B cells and application of the medicine and the method. The medicine for treating the diseases caused by autoantibodies generated by excessive proliferation of B cells comprises mRNA (messenger Ribonucleic Acid) for coding chimeric antigen receptor molecules and T cell targeting lipid nanoparticles, the drug can generate chimeric antigen receptor T cells in vivo; the lipid nanoparticles comprise cationic lipid, phospholipid, cholesterol, PEG lipid and targeting molecules, and the targeting molecules mediate T cell targeting. Lipid nanoparticles (mRNA-LNP) encapsulating chimeric antigen receptor molecules mRNA are used for delivering mRNA into in-vivo T cells to generate chimeric antigen receptor T cells, and pathological autoreactive B cells are removed to treat diseases caused by autoantibodies generated by excessive proliferation of the B cells.

The present invention relates to a diagnostic composition comprising at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VDELERIRRSILPYGDSMDRIEKDR), SEQ ID NO: 2 (GGAGSLGAGGAFGEA), SEQ ID NO: 35 (GPAGPPGHPGPPGPR), SEQ ID NO: 4 (EGLITLTELADSLLS), SEQ ID NO: 5 (EFQYLTGGLIEPQVH), SEQ ID NO: 6 (SSHMLTDTKTGLHFN), SEQ ID NO: 7 (FIPGPPGPPGPPGPR), SEQ ID NO: 8 (INEAIEQGTIDKALV), SEQ ID NO: 9 (AFGEAAGDRGPYGTDI) and SEQ ID NO: 10 (LITLTELADSLLSRL). Furthermore, the present invention relates to an in vitro method for detecting the presence or absence of a disease selected from the group of bullous pemphigoid, Parkinson's disease, and a neurological disorder comprising testing the binding of at least one peptide as identified in any of the preceding claims for binding to autoantibodies obtained from a subject suspected of suffering from one of said diseases.

The application provides a biomarker for assisting in diagnosing systemic lupus erythematosus and application thereof, proves that 15(S)-HETE has good diagnostic efficiency for systemic lupus erythematosus, and the diagnostic efficiency is improved after 15(S)-HETE is combined with anti-dsDNA antibody or anti-Smith antibody, has good diagnostic efficiency for systemic lupus erythematosus with negative specific autoantibody, and 15(S)-HETE can also reflect the disease activity of systemic lupus erythematosus.

To provide a new serum marker whose expression is restricted to the latent form of toxoplasmosis (bradyzoites / cysts). Also provided is an antibody that specifically binds to the new protein.SOLUTION: The present invention relates to a new Toxoplasma gondii protein, hereinafter referred to as BCLA, a new serum marker whose expression is restricted to the latent form of toxoplasmosis. This specific protein and its antigenic fragments can be used to detect autoantibodies in the serum of patients for the diagnosis of latent forms of toxoplasmosis. The invention also relates to derived antibodies generated by BCLA immunization that specifically bind to this new protein.SELECTED DRAWING: None

The present disclosure provides, inter alia, molecules comprising an autoantibody binding domain and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic autoantibodies.

A composition of matter including an anti-TSH receptor antibody-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting the anti-TSH receptor antibody-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing anti-TSH receptor autoantibody from a patient or subject, such as a Graves' disease or thyroid eye disease patient.

The present disclosure provides an ophthalmic formulation comprising: one or more pharmaceutically acceptable excipients; a pharmaceutically active compound capable of reducing the amount or deleterious effects of autoantibodies on the ocular surface, such as IgG; in particular, the present disclosure provides an ophthalmic formulation wherein the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular diseases that can cause symptoms of ocular discomfort, keratitis, dry eye disease, formation of symblepharon, shortening of the anterior chamber depth, lid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.